Endevica Bio Overview

  • Founded

  • 2009

Founded
  • Status

  • Private

  • Employees

  • 3

Employees
  • Latest Deal Type

  • Grant

  • Latest Deal Amount

  • $5.02M

  • Investors

  • 5

Endevica Bio General Information

Description

Developer of therapeutic drugs intended to treat cachexia due to cancer and other chronic conditions. The company's drugs are melanocortin-based peptide drugs for treating cardiovascular problems which are free from any adverse cardiovascular side effects, enabling healthcare practitioners to use these drugs for proper treatment of cancer and other chronic diseases.

Contact Information

Website
www.endevicabio.com
Formerly Known As
Tensive Controls
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 1601 South Providence Road
  • Columbia, MO 65211
  • United States
+1 (573) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Endevica Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 01-Jun-2017 $5.02M 00.000 Completed Generating Revenue
4. Later Stage VC (Series A) 01-Jun-2016 00.000 00.000 Completed Generating Revenue
3. Grant 01-Jan-2014 0000 Completed Generating Revenue
2. Grant 01-Jan-2012 $1.75M Completed Startup
1. Early Stage VC Completed Startup
To view Endevica Bio’s complete valuation and funding history, request access »

Endevica Bio Patents

  • 19

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Endevica Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170247414-A1 Anti-microbial peptides Granted 19-Sep-2014 00000000 0
EP-3194422-A4 Anti-microbial peptides Granted 19-Sep-2014 00000000
EP-3194422-A1 Anti-microbial peptides Granted 19-Sep-2014 00000000
EP-3194422-B1 Anti-microbial peptides Active 19-Sep-2014 00000000
US-20200109171-A1 Anti-microbial peptides Granted 19-Sep-2014 C07K7/08 0
To view Endevica Bio’s complete patent history, request access »

Endevica Bio Executive Team (6)

Name Title Board Seat Contact Info
Russell Potterfield Co-Chief Executive Officer & Executive Chairman
Jake Halliday Ph.D Co-Chief Executive Officer
Kenneth Gruber Ph.D Founder, President & Chief Scientific Officer
LeAnn Qi Chief Commercialization Officer
Michael Callahan Ph.D Vice President
You’re viewing 5 of 6 executive team members. Get the full list »

Endevica Bio Board Members (2)

Name Representing Role Since
Daniel Marks MD Endevica Bio Chief Medical Officer & Board Member 000 0000
Russell Potterfield Endevica Bio Co-Chief Executive Officer & Executive Chairman 000 0000
To view Endevica Bio’s complete board members history, request access »

Endevica Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Endevica Bio Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Centennial Investors Angel Group Minority 000 0000 000000 0
United States Department of Agriculture Government 000 0000 000000 0
National Cancer Institute Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Missouri Technology Corporation Venture Capital Minority 000 0000 000000 0
To view Endevica Bio’s complete investors history, request access »

Ready to get started?

Request a free trial